Durable survival with TRIDENT in treatment-naïve advanced NSCLC In our prospective phase I clinical trial ...
CXCR4 marks CD4+ memory T cells associated with AML remission To identify features linked to ...
Tuesday, January 6, 2026 For high-risk patients, the method could offer a safer alternative to ...